These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 28855578)

  • 21. Anti-cancer effects of the HuR inhibitor, MS-444, in malignant glioma cells.
    Wang J; Hjelmeland AB; Nabors LB; King PH
    Cancer Biol Ther; 2019; 20(7):979-988. PubMed ID: 30991885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methyl(R217)HuR and MCM6 are inversely correlated and are prognostic markers in non small cell lung carcinoma.
    Vigouroux C; Casse JM; Battaglia-Hsu SF; Brochin L; Luc A; Paris C; Lacomme S; Gueant JL; Vignaud JM; Gauchotte G
    Lung Cancer; 2015 Aug; 89(2):189-96. PubMed ID: 26013954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Farnesiferol c induces apoptosis via regulation of L11 and c-Myc with combinational potential with anticancer drugs in non-small-cell lung cancers.
    Jung JH; Kim MJ; Lee H; Lee J; Kim J; Lee HJ; Shin EA; Kim YH; Kim B; Shim BS; Kim SH
    Sci Rep; 2016 May; 6():26844. PubMed ID: 27231235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting the interaction between RNA-binding protein HuR and FOXQ1 suppresses breast cancer invasion and metastasis.
    Wu X; Gardashova G; Lan L; Han S; Zhong C; Marquez RT; Wei L; Wood S; Roy S; Gowthaman R; Karanicolas J; Gao FP; Dixon DA; Welch DR; Li L; Ji M; Aubé J; Xu L
    Commun Biol; 2020 Apr; 3(1):193. PubMed ID: 32332873
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytoplasmic overexpression of RNA-binding protein HuR is a marker of poor prognosis in meningioma, and HuR knockdown decreases meningioma cell growth and resistance to hypoxia.
    Gauchotte G; Hergalant S; Vigouroux C; Casse JM; Houlgatte R; Kaoma T; Helle D; Brochin L; Rech F; Peyre M; Labrousse F; Vallar L; Guéant JL; Vignaud JM; Battaglia-Hsu SF
    J Pathol; 2017 Aug; 242(4):421-434. PubMed ID: 28493484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer.
    Liu B; Pan CF; Ma T; Wang J; Yao GL; Wei K; Chen YJ
    Mol Med Rep; 2017 Oct; 16(4):4107-4112. PubMed ID: 29067469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic Anticancer Activity of Combined Use of Caffeic Acid with Paclitaxel Enhances Apoptosis of Non-Small-Cell Lung Cancer H1299 Cells in Vivo and in Vitro.
    Min J; Shen H; Xi W; Wang Q; Yin L; Zhang Y; Yu Y; Yang Q; Wang ZN
    Cell Physiol Biochem; 2018; 48(4):1433-1442. PubMed ID: 30064123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Luteolin Inhibits Tumorigenesis and Induces Apoptosis of Non-Small Cell Lung Cancer Cells via Regulation of MicroRNA-34a-5p.
    Jiang ZQ; Li MH; Qin YM; Jiang HY; Zhang X; Wu MH
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Posttranscriptional Regulation of
    Chand SN; Zarei M; Schiewer MJ; Kamath AR; Romeo C; Lal S; Cozzitorto JA; Nevler A; Scolaro L; Londin E; Jiang W; Meisner-Kober N; Pishvaian MJ; Knudsen KE; Yeo CJ; Pascal JM; Winter JM; Brody JR
    Cancer Res; 2017 Sep; 77(18):5011-5025. PubMed ID: 28687616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The expression of RNA-binding protein HuR in non-small cell lung cancer correlates with vascular endothelial growth factor-C expression and lymph node metastasis.
    Wang J; Zhao W; Guo Y; Zhang B; Xie Q; Xiang D; Gao J; Wang B; Chen Z
    Oncology; 2009; 76(6):420-9. PubMed ID: 19420963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long non-coding RNA FENDRR attenuates the stemness of non-small cell lung cancer cells via decreasing multidrug resistance gene 1 (MDR1) expression through competitively binding with RNA binding protein HuR.
    Gong F; Dong D; Zhang T; Xu W
    Eur J Pharmacol; 2019 Jun; 853():345-352. PubMed ID: 30981768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
    Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
    Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug delivery approaches for HuR-targeted therapy for lung cancer.
    Raguraman R; Shanmugarama S; Mehta M; Elle Peterson J; Zhao YD; Munshi A; Ramesh R
    Adv Drug Deliv Rev; 2022 Jan; 180():114068. PubMed ID: 34822926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suramin, screened from an approved drug library, inhibits HuR functions and attenuates malignant phenotype of oral cancer cells.
    Kakuguchi W; Nomura T; Kitamura T; Otsuguro S; Matsushita K; Sakaitani M; Maenaka K; Tei K
    Cancer Med; 2018 Dec; 7(12):6269-6280. PubMed ID: 30449075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of the mRNA-binding protein HuR as a novel reversal mechanism of epirubicin-triggered multidrug resistance in colorectal cancer cells.
    Lin GL; Ting HJ; Tseng TC; Juang V; Lo YL
    PLoS One; 2017; 12(10):e0185625. PubMed ID: 28968471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.
    Liu X; Yue P; Zhou Z; Khuri FR; Sun SY
    J Natl Cancer Inst; 2004 Dec; 96(23):1769-80. PubMed ID: 15572759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Loss of RNA binding protein, human antigen R enhances mitochondrial elongation by regulating Drp1 expression in SH-SY5Y cells.
    Bae JE; Park SJ; Hong Y; Jo DS; Lee H; Park NY; Kim JB; Park HJ; Bunch H; Chang JH; Lee EK; Cho DH
    Biochem Biophys Res Commun; 2019 Aug; 516(3):713-718. PubMed ID: 31253394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HuR-targeted nanotherapy in combination with AMD3100 suppresses CXCR4 expression, cell growth, migration and invasion in lung cancer.
    Muralidharan R; Panneerselvam J; Chen A; Zhao YD; Munshi A; Ramesh R
    Cancer Gene Ther; 2015 Dec; 22(12):581-90. PubMed ID: 26494555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment.
    Amreddy N; Babu A; Panneerselvam J; Srivastava A; Muralidharan R; Chen A; Zhao YD; Munshi A; Ramesh R
    Nanomedicine; 2018 Feb; 14(2):373-384. PubMed ID: 29155362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current Evidence and Future Perspectives on HuR and Breast Cancer Development, Prognosis, and Treatment.
    Kotta-Loizou I; Vasilopoulos SN; Coutts RH; Theocharis S
    Neoplasia; 2016 Nov; 18(11):674-688. PubMed ID: 27764700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.